Maryland strategist and former U.S. Department of Commerce official joins IndyGeneUS bio as it advances commercializing its next-generation intelligence.

Now comes the next chapter: demonstrating what those assets can unlock for the pharmaceutical industry and, ultimately, for patients.”

— Yusuf Henriques

BALTIMORE, MD, UNITED STATES, September 1, 2026 /EINPresswire.com/ — IndyGeneUS Bio today announced the appointment of Julius Maina, Founder and Principal of Maina Ventures, as Strategic Advisor, strengthening the company’s commercial leadership as it advances the Clinico-Genomic Insights Engine™ (CGIE™) toward strategic partnerships, pharmaceutical engagement, and broader market adoption.

Maina joins the company at a defining stage in its evolution. After years spent building representative genomic infrastructure, securing global institutional partnerships, and establishing one of the world’s largest representative genomic biorepositories, IndyGeneUS Bio is entering its next phase—transforming those assets into commercial opportunities that can accelerate therapeutic discovery and precision medicine.

As Strategic Advisor, Maina will work alongside executive leadership to strengthen commercialization strategy, cultivate strategic partnerships, identify non-dilutive capital opportunities, and position the company’s differentiated genomic intelligence platform for pharmaceutical companies, biotechnology innovators, healthcare systems, and institutional investors.

“Building the technology is only the beginning,” said Yusuf Henriques, Founder and Chief Executive Officer of IndyGeneUS Bio. “Creating lasting impact requires demonstrating commercial value. Julius understands how to connect innovation with capital, institutions, and strategic partnerships. His experience will help accelerate our transition from building the foundation to bringing representative genomic intelligence into the global life sciences marketplace.”

The appointment comes as advances in genome sequencing and artificial intelligence continue reshaping biomedical research. Sequencing has become faster, more affordable, and increasingly accessible, while AI is dramatically expanding what researchers can learn from large-scale genomic datasets.
At the same time, the value of genomic intelligence is becoming increasingly dependent on the breadth and diversity of the underlying data.

Despite decades of progress in precision medicine, many of the genomic datasets used throughout pharmaceutical research remain heavily concentrated in populations of European ancestry, limiting opportunities to identify novel biological targets and fully understand disease across global populations.
IndyGeneUS Bio was founded to change that.

Through its Clinico-Genomic Insights Engine™ (CGIE™), the company is developing secure infrastructure that connects representative genomic and clinical data within governed Trusted Research Environments, enabling pharmaceutical companies and researchers to generate actionable biological intelligence while maintaining responsible stewardship of sensitive health information.

Its growing ecosystem includes one of the world’s largest representative genomic biorepositories, anchored by partnerships in South Africa and Nigeria and complemented by a developing United States diaspora cohort. Together, these assets create a differentiated foundation for the next generation of precision medicine.

“For years, conversations around representation have focused primarily on equity,” said Julius Maina. “Today, representative data has become a strategic business asset. As sequencing costs decline and artificial intelligence expands what’s possible, organizations with differentiated genomic datasets will be positioned to unlock new scientific discoveries and create significant commercial value. IndyGeneUS Bio is building that future.”

The company’s commercialization strategy is supported by exclusive executed agreements backing its Representative Genomic BioRepository™ of more than one million verified whole-blood samples through partnerships with The Aurum Institute and Nigeria’s National Biotechnology Research and Development Agency (NBRDA). Combined with the intelligence capabilities of CGIE™, these assets position IndyGeneUS Bio to help pharmaceutical and biotechnology organizations discover novel biological targets, accelerate therapeutic development, and improve the efficiency of precision medicine.

For Henriques, whose vision for IndyGeneUS Bio was shaped by his experience navigating an inherited retinal disease diagnosis affecting his twin daughters, the appointment represents a significant milestone in the company’s evolution.

“We’ve spent years building access that didn’t previously exist, establishing trusted partnerships, and developing infrastructure designed for the future of precision medicine,” said Henriques. “The next chapter is execution. It’s about demonstrating the commercial value of representative genomic intelligence and creating opportunities that benefit pharmaceutical innovation while improving outcomes for patients. Julius brings the strategic perspective and commercial expertise to help us realize that vision.”

Maina brings decades of experience in strategic growth, entrepreneurship, public-private partnerships, capital formation, and economic development. His career includes leadership roles with the U.S. Department of Commerce’s Minority Business Development Agency and the U.S. Census Bureau, where he advised organizations on growth strategy, institutional partnerships, and access to capital. He also served as an Adjunct Professor at Morgan State University, mentoring entrepreneurs and future business leaders while helping bridge innovation, education, and economic development.

His appointment follows the recent addition of genomics pioneer Dr. George Church to IndyGeneUS Bio’s Scientific Advisory Board, reinforcing the company’s strategy of pairing world-class scientific leadership with experienced commercial execution. As IndyGeneUS Bio advances the commercialization of CGIE™, Maina’s appointment reflects the company’s continued evolution from building representative genomic infrastructure to delivering the intelligence, partnerships, and commercial capabilities required to shape the future of precision medicine.

About IndyGeneUS Bio
IndyGeneUS Bio is a BioFinTech™ company developing the Clinico-Genomic Insights Engine™ (CGIE™), a representative clinico-genomic intelligence platform designed to transform genomic and clinical data into actionable insights for drug discovery, diagnostics, clinical research, and precision medicine. Through representative genomic intelligence, IndyGeneUS Bio is helping pharmaceutical and biotechnology organizations accelerate discovery, improve therapeutic development, and build a more inclusive future for precision medicine.

About Maina Ventures
Maina Ventures is a strategic advisory firm that helps companies, institutions, and entrepreneurs translate emerging opportunities into fundable, scalable, and institutionally relevant growth strategies. Julius Maina’s advisory work with IndyGeneUS Bio is conducted through Maina Ventures in his private capacity.

Angel Livas
IndyGeneUS Bio
email us here

Legal Disclaimer:

EIN Presswire provides this news content “as is” without warranty of any kind. We do not accept any responsibility or liability
for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this
article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Media gallery

About The Author
Written By: EIN Presswire